Mechanism of action
The drug is a non-selective muscarinic receptor antagonist that blocks $M_1$, $M_2$, and $M_3$ receptor subtypes. The primary therapeutic effect is achieved by blocking $M_3$ muscarinic receptors in the smooth muscle of the bronchi, leading to their relaxation. An important feature is the hydrophilic nature of the molecule: due to the presence of a quaternary nitrogen atom, the drug penetrates biological membranes poorly, ensuring a predominantly local effect upon inhalation.
Pharmacological effects
The main effect is bronchodilation, most pronounced in large and medium-sized bronchi. Unlike many other agents, ipratropium does not suppress mucociliary clearance. However, the blockade of $M_3$ receptors in the mucosal glands leads to decreased secretion, which may increase sputum viscosity. Systemic effects with inhalation administration are virtually absent due to low absorption into the bloodstream.
Indications
Ipratropium bromide is the drug of choice in the treatment of COPD, as it effectively relieves the increased cholinergic influence of the vagus nerve on bronchial tone. It is also used in bronchial asthma and obstructive airway diseases. In ENT practice, it is used to reduce rhinorrhea in vasomotor rhinitis.
Side effects
Local side effects include dry mouth and increased sputum viscosity. Systemic atropine-like reactions (tachycardia, miosis, marked bronchospasm) are practically absent with correct inhalation use. The risk of systemic action increases if the drug deposited in the oropharynx is swallowed.
Prescription details
The standard dosage is 2 puffs (20 mcg each) 3–4 times daily. It is important to remember that during inhalation, only 10% of the substance reaches the small bronchi, while the rest settles in the oropharynx. To minimize systemic absorption, the elimination pathway of the drug via mucociliary clearance should be considered and swallowing avoided.
Briefly: answers to topical questions
What systemic atropine-like effects can occur with the resorptive action of ipratropium bromide?
When using ipratropium bromide, systemic atropine-like effects are virtually absent due to its low absorption. The drug is a hydrophilic compound that is poorly absorbed into the blood from the mucous membranes of the respiratory tract and from the intestine when swallowed. However, if resorptive action develops (blockade of peripheral muscarinic receptors), typical atropine-like effects may occur:
- Xerostomia — dryness of the mouth and mucous membranes.
- Ophthalmic disorders — mydriasis (pupillary dilation) and impaired accommodation.
- Urological disorders — urinary retention.
- Other effects — skin flushing and dryness, hyperthermia, psychomotor agitation, as well as impaired respiratory and cardiovascular function.
How does ipratropium bromide differ from tiotropium bromide?
The main differences between the drugs lie in their receptor profile, selectivity, and duration of therapeutic effect.
| Characteristic | Ipratropium bromide | Tiotropium bromide |
|---|---|---|
| Receptor profile | Non-selectively blocks all receptor subtypes ($M_1$, $M_2$, $M_3$) | Has kinetic selectivity for $M_1$ and $M_3$ muscarinic receptors |
| Effect on $M_2$ receptors | Blocks presynaptic $M_2$ receptors, enhancing acetylcholine release | Does not block presynaptic $M_2$ muscarinic receptors |
| Duration of action | Short-acting (6–8 hours) | Long-acting (approximately 12–24 hours) |
| Dosing regimen | Several times a day | Inhalation once daily |
With which bronchodilators from other groups is it advisable to combine ipratropium bromide?
It is advisable to combine ipratropium bromide with bronchodilators from the $\beta_2$-agonist group. Such a combination provides a dual mechanism of bronchodilation and mutual enhancement of the bronchodilating effect (synergism), and also makes it possible to reduce the dose of the $\beta_2$-agonist to minimize side effects. The sources list the following combinations:
- Fenoterol + ipratropium bromide (Berodual).
- Salbutamol + ipratropium bromide (Combivent).
Ipratropium — mnemonic "I-P-R-A" (in Russian): Inhalation, Drug of choice (COPD), Relaxes bronchi, Atropine-like (but local).
Class and exam questions
Why is ipratropium bromide considered safer than atropine for inhalation?
Ipratropium is a hydrophilic quaternary ammonium compound. It is poorly absorbed from mucous membranes and the gastrointestinal tract, thus acting locally without causing the systemic side effects typical of atropine.
How does ipratropium affect sputum viscosity?
The drug reduces the secretion of the bronchial glands, leading to a decrease in the volume of secretion and an increase in its viscosity, which may make it difficult to clear sputum.
Why is ipratropium the drug of choice in COPD?
In the pathogenesis of COPD, the excessive cholinergic influence of the vagus nerve on bronchial tone plays a key role. Anticholinergic agents effectively relieve this mechanism, providing sustained bronchodilation.
What else to study on this topic
- Comparison of the pharmacokinetics of ipratropium and tiotropium.
- Mechanisms of presynaptic $M_2$ receptor blockade and their impact on efficacy.
- The role of anticholinergic agents in combination therapy with $\beta_2$-agonists.
- Differences between tertiary and quaternary ammonium compounds in pharmacology.
- Causes of tachycardia upon systemic administration of anticholinergic agents.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Ipratropium bromide" and 5,304 more subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.